The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine

OncoTargets and Therapy

Volumn 4, Issue , 2011, Pages 115-121

  Ahmad, Ebtesam I ^a   Gawish, Heba H ^a   Al Azizi, Nashwa M A ^a   Elhefni, Ashraf M ^a  

^a Zagazig University   (Egypt)

Author keywords

Acute myeloid leukemia; Cytarabine (ara C); K RAS gene

Indexed keywords

CYTARABINE; DAUNORUBICIN; K RAS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER PROGNOSIS; CHROMOSOME G BAND; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SEX RATIO; TREATMENT OUTCOME;

EID: 81255158158     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S12602     Document Type: Article

References (27)

1. Chan IT, Kato JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113(4):528-538.
2. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
3. Haferlach T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2008:400-411.
4. Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf, MEK, and ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17(7):1263-1293.
5. Illmer T, Thiede C, Fredersdorf A, et al. Activation of the RAS pathway for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res. 2005;11(9):3217-3224.
6. Barletta E, Gorini G, Vineis P, et al. RAS gene mutations in patients with acute myeloid leukemia and exposure to chemical agents. Carcinogenesis. 2004;25(5):749-755.
7. Benanti JA, Galloway DA. The normal response to RAS: senescence or transformation? Cell Cycle. 2004;3(6):715-717.
8. Milella M, Komblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108(6):851-859.
9. Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol. 1997;15(1):285-291.
10. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074-3080.
11. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97(11):3589-3595.
12. Seabright M. A rapid banding technique for human chromosomes. Lancet. 1971;2(7731):971-972.
13. Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. Leukemia. 1994;8(10):1682-1687.
14. Tyner JW, Erichson H, Deininger MW, et al. High-throughput sequencing screen reveals novel transforming RAS mutations in myeloid leukemia patients. Blood. 2009;113(8):1749-1755.
15. Ritter M, Kim TD, Lisske P, Thiede C, Schaich M, Neubauer A. Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. Haematologica. 2004;89(11):1397-1399.
16. Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994;83(6):1603-1611.
17. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113-2119.
18. Valk PJ, Bowen DT, Frew ME, Goodeve AC, Lowenberg B, Reilly JT. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). Haematologica. 2004;89(1):106.
19. Schaich M, Ritter M, Illmer T, et al. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukemia. Br J Haematol. 2001;112(2):300-307.
20. Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/RAS signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003;102(4):1474-1479.
21. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101(2):597-602.
22. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006;107(10):3847-3853.
23. Koo HM, Monks A, Mikheev A, et al. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res. 1996;56(22):5211-5216.
24. Koo HM, McWilliams MJ, Alvord WG, Vande Woude GF. RAS oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1999;59(24):6057-6062.
25. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444(7119):638-642.
26. Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G, Fagin JA. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J Biol Chem. 2006:281(7):3800-3809.
27. Fikaris AJ, Lewis AE, Abulaiti A, Tsygankova OM, Meinkoth JL. Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling. J Biol Chem. 2006;281(46):34759-34767.